A study of blood vessel cells in women with advanced ovarian or womb cancer

Please note - this trial is no longer recruiting patients. We hope to add results when they are available.

Cancer type:

Ovarian cancer
Womb (uterine or endometrial) cancer





This study is looking at cells that have broken away from blood vessels Open a glossary item as a possible way of monitoring treatment for womb (endometrial) cancer, and the most common type of ovarian cancer called epithelial ovarian cancer.  

Cancers need a blood supply to help them grow and survive. So growing cancers encourage the growth of new blood vessels. This is called angiogenesis. Blood vessels are lined with cells called endothelial cells. When these cells are damaged, they are released into the bloodstream, and become circulating endothelial cells (CECs). Researchers have found increased numbers of CECs in people with cancer, which may be a sign (biomarker) that new blood vessels are being formed.  

Researchers in this study would like to find out more about how chemotherapy affects these cells. They will collect blood samples and medical information from women having chemotherapy for these cancers. They will count the numbers of CECs, and another type of endothelial cell from the bone marrow Open a glossary item called circulating endothelial progenitors (CEPs). They will also study the makeup of sugars in the bloodstream linked to CECs and CEPs.

You will not have any direct benefit from taking part in this study, and it is unlikely to change your treatment plan in any way. But the results of the study will be used to help people with cancer in the future.

Who can enter

You can enter this study if you

  • Have epithelial ovarian or womb (endometrial) cancer that has spread to another part of your body (advanced cancer)
  • Are about to start a course of chemotherapy
  • Are at least 18 years of age

You cannot enter this study if you

  • Have a condition that makes it difficult for you to give blood, for example clotting problems or difficult veins
  • Have hepatitis B, hepatitis C or HIV
  • Are having, or have just finished treatment with, heparin injections to thin your blood
  • Have a disease affecting your connective tissue Open a glossary item, for example lupus or rheumatoid arthritis Open a glossary item
  • Have problems with inflamed blood vessels
  • Have sickle cell disease
  • Have reduced kidney function – a blood test called a GFR Open a glossary item will show this

Trial design

This study will recruit 200 women.  Everyone taking part will give up to 2 blood samples before they start chemotherapy, and one sample during their course of chemotherapy.  

You will also give permission for the team to store these blood samples to use both now and in future research. And to collect information from your medical notes including about your cancer, treatment and test results.

Hospital visits

Where possible, you will give your study blood samples when you are already at the hospital for your treatment. So you should not need to make any extra visits to take part in this study.

Side effects

You may have a small bruise where you gave your blood sample.

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Professor Gordon Jayson

Supported by

Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer
The Christie NHS Foundation Trust

If you have questions about the trial please contact our cancer information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:

Oracle 7594

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Last reviewed:

Rate this page:

Currently rated: 5 out of 5 based on 1 vote
Thank you!
We've recently made some changes to the site, tell us what you think